| Members |
targetComponentId |
| Levofloxacin 5mg/mL infusion solution 100mL vial (product) |
Levofloxacin 5 mg/mL solution for injection |
| Levofloxacin 5mg/ml ophthalmic solution (product) |
Levofloxacin anhydrous (as levofloxacin) 5 mg/mL eye solution |
| Levoleucovorin calcium 50mg powder for injection solution vial (product) |
Levoleucovorin (as levoleucovorin calcium) 50 mg powder for solution for injection vial |
| Levomethadyl acetate hydrochloride 10mg/mL oral solution (product) |
Levomethadyl 10 mg/mL oral solution |
| Levonorgestrel 0.015mg/day + estradiol 0.045mg/day transdermal system (product) |
Estradiol 1.88 microgram/hour and levonorgestrel 625 nanogram/hour prolonged-release transdermal patch |
| Levonorgestrel 52mg intrauterine system (product) |
Product containing precisely levonorgestrel 833 nanogram/1 hour prolonged-release intrauterine drug delivery system (clinical drug) |
| Levothyroxine sodium 0.05mg tablet (product) |
Levothyroxine sodium anhydrous 50 microgram oral tablet |
| Levothyroxine sodium 0.075mg tablet (product) |
Levothyroxine sodium anhydrous 75 microgram oral tablet |
| Levothyroxine sodium 0.1mg tablet (product) |
Levothyroxine sodium anhydrous 100 microgram oral tablet |
| Levothyroxine sodium 200mg tablet (product) |
Product containing precisely levothyroxine sodium 200 microgram/1 each conventional release oral tablet (clinical drug) |
| Levothyroxine sodium o.05mg (product) |
Levothyroxine sodium anhydrous 50 microgram oral tablet |
| Leydig cell neoplasm of testis (disorder) |
Leydig cell tumor of testis of uncertain behavior |
| Leydig cell tumor, no International Classification of Diseases for Oncology subtype (morphologic abnormality) |
Leydig cell tumor of uncertain behavior (morphologic abnormality) |
| lichen scléroatrophique |
lichen scléreux et atrophique (trouble) |
| Lichen sclerosus et atrophicus of the vulva |
lichen scléreux vulvaire |
| Lichen sclerosus et atrophicus, bullous type |
Lichen sclerosus bullous type (disorder) |
| Liddle's syndrome (disorder) |
Pseudoprimary hyperaldosteronism (disorder) |
| Lidocaine 1%/epinephrine (1:200000) injection solution 20mL vial (product) |
Product containing only epinephrine and lidocaine in parenteral dose form (medicinal product form) |
| Lidocaine 1.5% injection solution vial (product) |
Lidocaine only product in parenteral dose form |
| Lidocaine 2%/epinephrine (1:200000) injection solution 20mL vial (product) |
Epinephrine (as epinephrine bitartrate) 5 microgram/mL and lidocaine hydrochloride 20 mg/mL solution for injection |
| Lidocaine 2.5% topical ointment (product) |
Lidocaine hydrochloride 25 mg/g cutaneous ointment |
| Lidocaine 2.5%/prilocaine 2.5% periodontal gel (product) |
Lidocaine 25 mg/mL and prilocaine 25 mg/mL dental gel |
| Lidocaine hydrochloride 0.1%/glucose 5% infusion solution bag (product) |
Product containing precisely lidocaine hydrochloride 1 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Lidocaine hydrochloride 0.2%/glucose 5% infusion solution bag (product) |
Lidocaine hydrochloride 2 mg/mL solution for injection |
| Lidocaine hydrochloride 0.4%/glucose 5% infusion solution bag (product) |
Lidocaine only product in parenteral dose form |
| Lidocaine hydrochloride 0.5% injection solution ampule (product) |
Lidocaine only product in parenteral dose form |
| Lidocaine hydrochloride 0.5% injection solution vial (product) |
Lidocaine only product in parenteral dose form |
| Lidocaine hydrochloride 0.6%/glucose 5% infusion solution bag (product) |
Product containing precisely lidocaine hydrochloride 6 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Lidocaine hydrochloride 1% conventional release solution for injection ampule (product) |
Lidocaine only product in parenteral dose form |
| Lidocaine hydrochloride 1% injection (product) |
Product containing precisely lidocaine hydrochloride 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Lidocaine hydrochloride 1% injection solution ampule (product) |
Lidocaine only product in parenteral dose form |
| Lidocaine hydrochloride 1% injection solution sterile ampule (product) |
Lidocaine only product in parenteral dose form |
| Lidocaine hydrochloride 1% injection solution vial (product) |
Product containing precisely lidocaine hydrochloride 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Lidocaine hydrochloride 1%/epinephrine 1:100,000 injection solution vial (product) |
Epinephrine 10 microgram/mL and lidocaine hydrochloride 10 mg/mL solution for injection |
| Lidocaine hydrochloride 1%/epinephrine 1:200,000 injection solution vial (product) |
Product containing only epinephrine and lidocaine in parenteral dose form (medicinal product form) |
| Lidocaine hydrochloride 1.5% injection solution ampule (product) |
Lidocaine only product in parenteral dose form |
| Lidocaine hydrochloride 1.5%/epinephrine 1:200,000 injection solution vial (product) |
Product containing only epinephrine and lidocaine in parenteral dose form (medicinal product form) |
| Lidocaine hydrochloride 10%/epinephrine 0.1% topical iontophoretic patch (product) |
Product containing precisely epinephrine 1 microgram/1 milligram and lidocaine hydrochloride 100 microgram/1 milligram conventional release cutaneous patch (clinical drug) |
| Lidocaine hydrochloride 2% injection (product) |
Lidocaine only product in parenteral dose form |
| Lidocaine hydrochloride 2% injection solution 5 mL ampule (product) |
Product containing precisely lidocaine hydrochloride 20 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Lidocaine hydrochloride 2% injection solution ampule (product) |
Lidocaine only product in parenteral dose form |
| Lidocaine hydrochloride 2% injection solution vial (product) |
Product containing precisely lidocaine hydrochloride 20 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Lidocaine hydrochloride 2%/epinephrine 1:100,000 injection solution vial (product) |
Epinephrine 10 microgram/mL and lidocaine hydrochloride 20 mg/mL solution for injection |
| Lidocaine hydrochloride 2%/epinephrine 1:200,000 injection solution vial (product) |
Product containing only epinephrine and lidocaine in parenteral dose form (medicinal product form) |
| Lidocaine hydrochloride 2%/epinephrine 1:500,000 injection solution vial (product) |
Epinephrine 2 microgram/mL and lidocaine hydrochloride 20 mg/mL solution for injection |
| Lidocaine hydrochloride 4% injection solution ampule (product) |
Lidocaine hydrochloride 40 mg/mL solution for injection |
| Lidocaine hydrochloride 5% injection solution |
Lidocaine only product in parenteral dose form |
| Lidocaine hydrochloride 5%/glucose 7.5% injection solution vial (product) |
Lidocaine hydrochloride 50 mg/mL solution for injection |
| Lidocaine hydrochloride+epinephrine 0.5%/1:200,000 injection |
Product containing precisely epinephrine (as epinephrine bitartrate) 5 microgram/1 milliliter and lidocaine hydrochloride 5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Lidocaine hydrochloride+epinephrine 1%/1:100,000 injection (product) |
Epinephrine 10 microgram/mL and lidocaine hydrochloride 10 mg/mL solution for injection |
| Lidocaine hydrochloride+epinephrine 2%/1:80,000 cartridge (product) |
Product containing precisely epinephrine 12.5 microgram/1 milliliter and lidocaine hydrochloride 20 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Lidocaine hydrochloride+epinephrine 4% conventional release nasal drops |
Epinephrine and lidocaine only product |
| Lidocaine hydrochloride+epinephrine 4% preservative free nasal drops (product) |
Epinephrine and lidocaine only product |
| Lidocaine hydrochloride+fluorescein sodium 4%/0.25% conventional release eye drops (product) |
Fluorescein stain and lidocaine only product |
| Lidocaine hydrochloride+fluorescein sodium 4%/0.25% single-use eye drops |
Fluorescein stain and lidocaine only product |
| Liepmann's apraxia |
Transcortical apraxia |
| Lignocaine 5% / Hydrocortisone acetate 0.275% ointment (product) |
Hydrocortisone acetate 2.75 mg/g and lidocaine hydrochloride 50 mg/g cutaneous ointment |
| Lignocaine hydrochloride 1% injection(plastic amp) (product) |
Lidocaine only product in parenteral dose form |
| Lignocaine hydrochloride+adrenaline 2%/1:200000 sterile wrapped injection (product) |
Product containing only epinephrine and lidocaine in parenteral dose form (medicinal product form) |
| Lignocaine hydrochloride+glucose 5%/7.5% injection (product) |
Lidocaine hydrochloride 50 mg/mL solution for injection |
| Lincomycin 300mg/mL injection (product) |
Lincomycin only product in parenteral dose form |
| Lincomycin hydrochloride 300mg/mL injection solution ampule (product) |
Lincomycin only product in parenteral dose form |
| Linezolid 100mg/5mL granules for oral suspension (product) |
Product containing precisely linezolid 20 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Linezolid 100mg/5mL granules for oral suspension (product) |
Product containing precisely linezolid 20 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Linezolid 100mg/5mL suspension (product) |
Product containing precisely linezolid 20 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Linezolid 2mg/mL infusion solution 300mL bag (product) |
Product containing precisely linezolid 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Liothyronine sodium preparation (product) |
liothyronine |
| Lip and oral cavity TNM finding (finding) |
American Joint Committee on Cancer allowable value |
| Lip flap |
Flap (substance) |
| Lipoma of spinal column |
Lipoma of spinal cord |
| Liposarcoma, no International Classification of Diseases for Oncology subtype |
Liposarcoma |
| Liposomal daunorubicin 2mg/mL injection emulsion (product) |
Product containing only daunorubicin liposome in parenteral dose form (medicinal product form) |
| Liposomal doxorubicin hydrochloride 2mg/mL infusion concentrate 10mL vial (product) |
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Liposomal doxorubicin hydrochloride 2mg/mL infusion concentrate 25mL vial (product) |
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Liquid paraffin [eye] (product) |
Product containing mineral oil (medicinal product) |
| Liquid paraffin [laxative] (product) |
Product containing mineral oil (medicinal product) |
| Liraglutide 6mg/mL injection solution (product) |
Product containing only liraglutide (medicinal product) |
| Lisinopril allergy |
Non-allergic hypersensitivity to lisinopril |
| Listeria murrayi |
Listeria grayi |
| Lithium carbonate 300mg m/r tablet (product) |
Product containing only lithium carbonate in oral dose form (medicinal product form) |
| Lithium carbonate 300mg prolonged-release oral tablet |
Product containing only lithium carbonate in oral dose form (medicinal product form) |
| Livedoid vasculitis of lower limb due to varicose veins of lower limb (disorder) |
Livedoid vasculopathy of lower limb due to varicose veins of lower limb (disorder) |
| Lively splinting |
Dynamic splinting |
| Liver TNM finding (finding) |
American Joint Committee on Cancer allowable value |
| Liver abscess - excluding amebic liver abscess |
abcès du foie |
| Liver derivative complex 25.5mg injection (product) |
Liver extract only product |
| Liver derivative complex 25.5mg/mL injection solution ampule (product) |
Liver extract only product |
| Living on the street (finding) |
sans abri |
| Living organism (organism) |
organisme |
| Living organism category not applicable |
organisme |
| Living organism not assigned code in SNOMED |
organisme |
| Living organism not assigned to a scientific category |
organisme |
| Living organism not identified |
No living organism identified (finding) |
| Lloyd's syndrome (disorder) |
polyendocrinopathie auto-immune |
| Lobster - dietary |
Lobster (substance) |
| Local advancement flap |
Reconstruction using local advancement flap (procedure) |
| Local convulsion (disorder) |
Partial seizure |
| Local cyst of bone (morphologic abnormality) |
Bone cyst |
| Local fasciocutaneous flap NOS |
Local fasciocutaneous flap |
| Local fasciocutaneous flap to head or neck NEC |
Local fasciocutaneous flap |
| Local flap of skin to head or neck NEC |
Reconstruction with local flap |
FHIR